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1. INTRODUCTION 
               Among all the neurological diseases of adult life, cerebrovascular  
accidents clearly ranks first in frequency of importance. Atleast fifty percent of 
neurological diseases in general hospital are due to stroke. Cerebrovascular 
accident includes ischemic stroke, hemorrhagic stroke, and cerebrovascular 
anomalies such as intracranial aneurysm, AV malformation and cortical 
venous thrombosis. Stroke, after heart disease and cancer, is the third most 
common cause of death (1). With the introduction of effective treatment for 
hypertension, there has been a marked reduction in the frequency of stroke. 
                  Diabetes mellitus by virtue of its association with micro vascular 
and macrovascular complications is an important risk factor in the genesis of 
stroke(2). Most of the diabetic patients with stroke have raised glycosylated 
haemoglobin indicating that most of them have uncontrolled diabetes. 
Diabetics and stress  hyperglycemics have severe strokes resulting in poor 
outcome. Stroke is twice more common in diabetics than in non diabetics(3). 
Hypertension is common in diabetes and accelerates atherosclerosis which 
promotes intracranial small vessel disease and heart disease leading to lacunar 
and embolic infarction respectively. There are several risk factors that 
determine the outcome of stroke hyperglycemia at presentation, hypertension, 
hypothermia, fever are those which are widely studied. 
 
2. REVIEW OF LITERATURE 
DEFINITION : 
Stroke (cerebro vascular accident) is a rapidly developing episode of 
focal and at times global loss of cerebral function with symptoms lasting more 
than 24hours or leading to death with no apparent cause other than that of 
vascular origin(4).  
Transient ischemic attack (TIA) is an acute loss of focal cerebral or 
monocular function with symptoms lasting less than 24hours. 
Reversible ischemic neurological deficit (RIND) refers to neurological 
deficit that disappears within 7 days of onset. 
EPIDEMIOLOGY 
RISK FACTORS (5) 
NON MODIFIABLE RISK FACTORS 
        Age: Increasing age is most powerful risk factor for cerebral infarction, 
intracerebral hemorrhage and subarachnoid hemorrhage as well as TIA. 
Sex: Men are more at risk for ischemic stroke than woman up to 75 
years of age. 
Race: The risk is more in Blacks than Whites. 
Family history: There is an increased incidence of stroke in individuals 
who have a first degree relative affected with stroke or who have paternal or 
maternal history of death or disability due to stroke. 
MODIFIABLE RISK FACTORS 
Hypertension: It is the most important predisposing factor not only for 
cerebral hemorrhage but also for infarction. Both systolic and diastolic 
pressures contribute to the risk though there is no critical level above which it 
operates. The reduction of BP by 10-12mmHg systolic and 5-6mmHg diastolic 
was found to be associated with 38% reduction in stroke incidence. 
Diabetes mellitus: It is an independent risk factor for stroke. It 
increases the susceptibility to coronary, femoral, and cerebral atherosclerosis. 
The relative risk increases two to fourfold in diabetic patients with diabetic 
complications like retinopathy, nephropathy and autonomic neuropathy have a 
higher incidence of ischemic stroke. 
Hyperglycemia and Stroke :  Elevated blood glucose is common in the 
early phase of stroke.  The prevalence of hyperglycemia defined as blood 
glucose level more than 6.1mmol/l has been observed in two third of all 
ischemic stroke subtypes on admission and in atleast fifty percent in each 
subtype including lacunar stroke(6).  Exclusive experimental evidence in 
stroke models support that association between blood glucose and functional 
outcome has been found in increasing number of clinical studies. 
Dyslipidemia: It is a secondary risk factor indirectly affecting the risk 
of stroke. Reducing high cholesterol levels decreases the incidence of coronary 
artery disease which is the main cause of mortality in patients with cerebro 
vascular disease. 
Non valvular atrial fibrillation: It is common in the age group of 65 – 
85years and attributes to a fivefold increase in the incidence of embolic stroke 
especially in those patients who have recent CCF, arterial hypertension and 
prior thromboembolism. 
Cigarette smoking: It increases the risk of infarction in men and 
women by predisposing to carotid atherosclerosis. Smokers experience a 
reduction in stroke risk only after 5 years following cessation of smoking. 
Alcohol: Light to moderate intake reduces the risk by increasing the 
HDL concentration, whereas heavy drinking increases the risk. More than one 
drink per day for women and more than two per day for men increases the BP, 
obesity and triglycerides level thereby increasing the risk. 
TIA: Three times greater risk for subsequent stroke or death due to 
vascular causes, especially those with hemispherical TIA. Patients with a 
previous history of stroke are at risk for a subsequent stroke. The risk of stroke 
recurrence is increased by the presence of dementia. 
Carotid artery stenosis: Asymptomatic carotid artery stenosis less than 
75% carries a risk of 1.3% annually whereas risk increases to 10.5% per year if 
the stenosis is greater than 75%. Ulcerated echoluscent and heterogeneous 
plaques with a soft-core are at higher risk for embolism. 
Blood factors: Elevated haematocrit, hemoglobin and viscosity of the 
blood is associated with increased risk of ischemic stroke. Higher mean levels 
of plasma fibrinogen, factor VIII, von willebrand’s factor, anti-thrombin III 
and lower mean levels of protein C is associated with increased risk. The 
antiphospholipid antibodies is associated with increased risk of ischemic 
stroke. Serum folate concentration less than or equal to 9.2 nmol/L alone may 
be risk factor for ischemic stroke. 
Hormones: High dose estrogen, oral contraceptives increases the risk of 
stroke in young women, while postmenopausal estrogen supplementation 
reduces the risk. The risk of cerebral infarction is increased in the first 6 weeks 
following delivery. 
Others: Abdominal or truncal obesity, physical inactivity, habitual 
snoring are associated with increased risk of ischemic stroke. 
Common Causes Uncommon Causes 
Thrombosis 
Lacunar stroke (small vessel) 
Large vessel thrombosis 
Dehydration 
Embolic occlusion 
Artery-to-artery 
Carotid bifurcation 
Aortic arch 
Arterial dissection 
Cardioembolic 
Atrial fibrillation 
Mural thrombus 
Myocardial infarction 
Dilated cardiomyopathy 
Valvular lesions 
Hypercoagulable disorders 
Protein C deficiency 
Protein S deficiency 
Antithrombin III deficiency 
Antiphospholipid syndrome 
Factor V Leiden mutation 
Systemic malignancy 
Sickle cell anemia 
Thalassemia 
Polycythemia vera 
Systemic lupus erythematosus 
Homocysteinemia 
Thrombotic thrombocytopenic purpura 
Disseminated intravascular coagulation 
Dysproteinemias 
Common Causes Uncommon Causes 
Mitral stenosis 
Mechanical valve 
Bacterial endocarditis 
Paradoxical embolus 
Atrial septal defect 
Patent foramen ovale 
Atrial septal aneurysm 
Spontaneous echo contrast 
Nephrotic syndrome 
Inflammatory bowel disease 
Oral contraceptives 
Venous sinus thrombosis 
Fibromuscular dysplasia 
Vasculitis 
Systemic vasculitis [PAN, granulomatosis 
with polyangiitis (Wegener's), Takayasu's, 
giant cell arteritis] 
Primary CNS vasculitis 
Meningitis (syphilis, tuberculosis, fungal, 
bacterial, zoster) 
Cardiogenic 
Mitral valve calcification 
Atrial myxoma 
Intracardiac tumor 
Marantic endocarditis 
Libman-Sacks endocarditis 
Subarachnoid hemorrhage  
Drugs: cocaine, amphetamine 
Moyamoya disease 
Eclampsia 
 
CLINICAL SYNDROMES (5) 
TRANSIENT ISCHAEMIC ATTACKS 
TIAs are abrupt in onset, brief in duration and recovery is possible in 24 
hours. Recurrent TIAs can occur. Recognition and treatment is important as a 
complete stroke can be prevented. 
Carotid TIAs 
These are characterized by monocular blindness with recovery within 
few minutes, visual field disturbance in the form of transient hemianopia and 
speech disturbance due to dominant hemispherical dysfunction. Hemi paresis 
and hemi sensory loss can occur both in vertebro basilar TIAs as well as 
carotid TIAs. 
Vertebro Basilar TIAs 
These are characterized by prominent visual symptoms like diplopia, 
homonymous hemianopia and cortical blindness, transient vertigo, dizziness, 
unsteadiness due to cerebellar dysfunction and transient lower cranial nerve 
symptoms like dysarthria, perioral numbness, nasal regurgitation. Drop attacks 
occur without any warning.  It is thought to be due to ischemia of relays in 
reticular systems which normally function as part of reflex antigravity 
mechanism. 
Subclavian steal syndrome 
This syndrome occurs when there is occlusion of the subclavian artery 
proximal to origin of vertebral artery which results in retrograde flow of blood 
down the vertebral artery during exercising the arm thereby leading on to 
symptoms of hindbrain ischemia. 
Mini Strokes 
Mini strokes are characterized by episodic ischemic symptoms which 
recover within 24 hours but there are small infarcts or hemorrhage in CT and 
are as significant as the TIAs. 
 
 
Stroke in evolution 
Stroke in evolution refers to the slow progression of neurological deficit 
over several hours. 
Major strokes 
Major stroke are of sudden onset with loss of consciousness at the onset 
or soon after. It is very difficult to distinguish clinically between infarction or 
hemorrhage. Headache and vomiting if present, usually denotes hemorrhage 
especially if it is associated with rapid loss of consciousness. Athero –
thromboembolism is suggested by the presence of bruit over the carotid 
arteries. 
Unusual types of stroke 
Multi-infarct dementia, watershed infarction. 
Classification of stroke on the basis of oxford shire community stroke 
Sub classification (7) 
Total anterior circulation syndrome (TACS) 
Implies a large cortical stroke in middle cerebral or middle and anterior 
cerebral artery territories. It is characterized by a combination of 
� new higher cerebral dysfunction 
� homonymous visual field defect 
� an ipsilateral motor and / or sensory deficit involving at least two out 
of three areas of the face , arm or legs 
Partial anterior circulation syndrome 
Implies a cortical stroke in middle or anterior cerebral arterial territory. 
This includes patients with two out of three components of the total anterior 
circulation syndromes or new higher cerebral dysfunction alone or motor / 
sensory deficit more restricted than those classified as a TACS 
Lacunar syndrome 
Implies a sub cortical stroke due to a small vessel disease 
• pure motor stroke 
• pure sensory stroke 
• sensory motor stroke 
• ataxic hemi paresis 
Evidence of higher cortical dysfunction or disturbance of consciousness 
excludes lacunar syndrome. 
Posterior circulation syndrome 
1. Ipsilateral cranial nerve palsy with contralateral motor and sensory deficit. 
2. Bilateral motor and or sensory deficit 
3. Disorder of conjugate eye movement 
4. Cerebellar dysfunction without ipsilateral long tract involvement 
5. Isolated homonymous visual field defects 
 
 
Pathophysiology of stroke 
Stroke is 90% ischaemic and 10% hemorrhagic(8).  Ischemic  stroke  
occurs because of a loss of blood supply to the brain, initiating the ischemic 
cascade. Brain tissue stops its function if lack of oxygen for more than 60 to 90 
seconds and after several hours will endure irreversible damage possibly 
leading to death of the tissue, i.e., infarction. Atherosclerosis may interfere the 
blood supply by causing the shaping of blood clots in the vessel, or narrowing 
the lumen of blood vessels, or releasing showers of small emboli through the 
disintegration of atherosclerotic plaques. Embolic infarction takes place when 
emboli formed anywhere else in the circulatory system, especially in the heart 
as a result of atrial fibrillation, or in the carotid arteries. These break-offs, get 
into the cerebral circulation, then lodge in and block brain blood vessels. 
Due to collateral circulation, there is a spectrum of severity within the 
region of brain tissue affected by ischemia. Therefore, part of the tissue may 
die in a short time while other parts may only be damaged and could 
potentially recover. The ischemic area where tissue might get recovery is 
called the “ischemic penumbra”(9). 
As glucose or oxygen becomes exhausted in ischemic brain tissue, the 
production of high energy phosphate compounds such as ATP fails, resulting 
in the failure of energy-dependent process necessary for tissue cell survival. 
This sets off a set of co-related events that bring about cellular injury and 
death. A main cause of neuronal injury is the release of excitatory 
neurotransmitter, glutamate. The concentration of glutamate outside the cells 
of nervous system is normally in a low amount as a result of so-called uptake 
carriers. However, stroke cuts off the supply of glucose and oxygen. Therefore 
the transmembrane ion gradients run down, and glutamate transporters reverse 
direction, releasing glutamate into the extracellular area. Glutamate works on 
receptors in nerve cells, producing an influx of calcium which activates 
enzymes that digest the proteins, lipids and nuclear material of the cells. 
Calcium influx can cause the failure of mitochondria as well, which may lead 
further to energy depletion and can trigger cell death out of apoptosis. 
Ischemia may also induce production of oxygen-free radicals and other 
reactive oxygen species. These react with and injure a quantity of cellular and 
extracellular elements. Damage to the blood vessel endothelium or lining is of 
importance. Actually, many antioxidant neuro protectants such as NXY-059 
and uric acid, work at the level of the endothelium instead of in the brain per 
se, as well free radicals initiate elements of the apoptosis cascade in a direct 
way by ways of redox signalling. 
In addition to injurious effects of brain cells, ischemia and infarction can 
lead to loss of structural integrity of brain tissue and blood vessels, partly 
through the release of matrix metalloproteases, which are zinc and calcium-
dependent enzymes that may break down hyaluronic acid, collagen, and other 
elements of connective tissue. Other proteases contribute to this process as 
well. The loss of vascular structural integrity leads to a breakdown of the 
protective blood brain barrier which contributes to cerebral edema, which may 
cause secondary progression of the brain injury. 
As is the case with any kind of brain injury, the immune system is 
activated by cerebral infarction and may under some circumstances exacerbate 
the injury caused by the infarction. Inhibition of the inflammatory response has 
been shown to reduce tissue injury due to cerebral infarction in the experiment, 
but this has not been testified in clinical studies. 
Hemorrhagic stroke 
Hemorrhagic stroke leads to tissue injury by causing compression of 
tissue from an expanding hematoma. The pressure may cause a loss of blood 
supply to affected tissue with infarction, and the blood released by brain 
hemorrhage appears to have direct toxic effects on vasculature and brain 
tissue. 
Based on these facts the concept of ischemic penumbra was formulated. 
It is an area of brain that has reached the reversible stage of electrical failure 
but has not yet passed into the irreversible stage. Thrombolytic agents are used 
in this time window to salvage the ischemic penumbra zone. 
 
 
Pathophysiology of hyperglycemia: 
Overview of glucose metabolism 
In healthy individuals without DM, the regulation of blood glucose 
concentration is maintained through hormonal, neural, and hepatic auto 
regulatory mechanisms (Robinson & van Soeren, 2004)(10). Under normal 
circumstances, a postprandial increase in blood glucose concentration 
stimulates the release of insulin from the pancreas, specifically the beta cells. 
Insulin mediates peripheral glucose disposal and suppresses glucogenesis in 
the liver. This process maintains blood glucose homeostasis. After uptake into 
the skeletal muscle, glucose either is directed to glucagon formation (pathway 
for carbohydrate storage) or glycolysis (used in the Kreb's cycle, resulting in 
energy production). Excess glucose also can be stored in the liver or converted 
to fatty acids for storage in adipose tissue. 
Altered glucose metabolism in critical illness: 
Critical illness induces a number of adaptive changes in human 
physiology; the most prominent are changes in the neuroendocrine function 
(Ferrando, 1999)(11). An increase in counter regulatory hormones, such as 
glucagon, epinephrine, norepinephrine, and growth hormone, results in 
increased hepatic glucose production and decreased peripheral glucose uptake, 
subsequently inducing a hyperglycemic state (Montori, Bistrian, & McMahon, 
2002)(12). In addition, critical illness exacerbates the circulation of abnormal 
levels of cytokines-particularly tumor necrosis factor, alpha, and interleukin—
further elevating serum glucose (McCowen, Malhotra, & Bistrian, 2001)(13). 
Patients with DM exhibit a greater response to counter regulatory hormones, 
and may not increase insulin secretion as a compensatory response to needed 
levels, resulting in even higher glucose levels (Montori et al., 2002). 
Effects of exogenous insulin: 
In global ischemia (e.g., anoxic brain injury and encephalopathy), 
insulin acts directly on brain parenchyma to reduce neuronal necrosis in the 
brain cortex, striatum, and hippocampus (Auer, 1998)(14). Animal data 
indicate that the direct mechanism is mediated by insulin-like growth factor-1 
receptors. The direct effect appears to predominate in global ischemia. In focal 
ischemia, unlike global ischemia, the effect of insulin is predominantly via 
peripheral hypoglycemia because neuroprotection largely is annulled by 
coadministration of glucose (Auer, 1998). Insulin also has been shown to 
improve cell membrane stability, assisting with cerebral edema resolution 
(American Association of Clinical Endocrinologists, 2003)(15). 
Hyperglycemia as a manifestation of the stress response is most evident 
after an ICU admission and may resolve as the underlying catabolic illness 
subsides (McCowen et al. 2001). Multiple factors have been associated with an 
increased risk of hyperglycemia in critical illness, including frequent 
administration of exogenous dextrose through intravenous drip, intravenous 
medications and antibiotics in dextrose solutions, glucocorticoid medication, 
catecholamine vasopressors, total parenteral nutrition administration (TPN), as 
well as increased age and prolonged bed rest. 
  Some patients, particularly those with an untreated underlying process 
such as infection or ongoing injury, may demonstrate persistent metabolic 
disregulation and continued hyperglycemia (McCowen et al., 2001).  
HbA1C: 
 HbA1C is structurally similar to hemoglobin A except for the addition 
of glucose Group to the terminal amino acid of the beta chain of the 
haemoglobin Molecule (glycosylation). Therefore HbA1C is a function of the 
exposure of the red blood cells to glucose. Since the glucose linkage to 
hemoglobin is relatively stable, HbA1C cumulates through out of the life span 
of erythrocyte and its concentration reflects the integrated blood glucose 
concentration over a period approximating to the half life of erythrocytes i.e. 
six to eight weeks. Therefore measurement of HbA1C helps to monitor the 
overall degree of diabetic control achieved. The normal range of HbA1C is 
3.8% to 6.4% 
Hyperglycemic Effects on the Injured Brain 
The effects of hyperglycemia on the injured brain have been studied in 
both animals and humans. Hyperglycemia has been associated with increased 
cerebral lactate resulting in local brain tissue acidosis (Kagansky, Levy, & 
Knobler, 2001)(16). Brain tissue acidosis worsens mitochondrial function in 
the penumbra, the moderately ischemic tissue of the brain surrounding the 
injured core, and increases cerebral infarct size (Alvarez-Sabín et al., 
2003)(17). In a study of 63 patients with sudden-onset focal neurological 
deficit consistent with hemispherical ischemic stroke who received serial MRI, 
hyperglycemia was shown to reduce penumbral salvage, resulting in greater 
final infarct size (Parsons et al., 2002)(18). 
Hyperglycemia also adversely affects the ischemic brain by disrupting 
the blood-brain barrier and promoting cerebral edema. In their study of rats 
with hemorrhagic stroke and hyperglycemia, Song et al. (2003) found that 
hyperglycemia-induced brain injury resulted in increased free radical 
formation(19). In turn, the increased amount of free radical formation 
increased blood-brain barrier permeability and brain edema. The authors 
hypothesized that elevated glucose levels aggravated brain edema, which 
culminated in cell death surrounding hemorrhagic stroke tissue. 
Insulin resistance is a known risk factor for the onset of stroke acting 
through a number of intermediate vascular disease risk factors (i.e. 
thrombophilia, endothelial dysfunction and inflammation (20).  The evolution 
of acute infarction may be explained by the very same vascular factors, 
explaining why ischemic time seems to fly faster in patients with diabetes or 
grave hyperglycemia. Relative insulin deficiency liberates circulating free fatty 
acids, which together with hyperglycemia, diminishes vascular reactivity(21). 
Furthermore, lowering glucose with insulin has been reported to reduce 
ischemic brain damage in an animal model(22). 
The evolution of an infarction is accompanied by glutamate release 
which is believed to propagate the necrosis of penumbral tissues. Although 
hyperglycemia alone did not trigger early response genes in cortical tissues of 
rats  the expression of c-fos and cox-2 were substantially increased (23) 
This suggested that increased glucose may trigger untoward intracellular 
biochemical cascades also by altering early gene expression in metabolically 
challenged neurons. 
Genome-wide association studies (GWAS) 
Genome-wide association studies (GWAS) revealed both their promise 
and limitations as an approach to understand the genetic architecture of stroke. 
The promise of GWAS lies in their extraordinary power to detect novel 
biologic loci that, if replicated, can serve as markers for novel genes, proteins, 
and ultimately mechanisms of disease. In this regard, since our previously 
yearly review, new GWAS from 2009 suggested that loci on chromosomes 
4q25 (PITX2 gene, encoding a β-catenin–regulated transcription factor 
associated with atrial fibrillation), 16q22 (ZFHX3 gene, encoding a 
homeodomain zinc-finger protein that has also been associated with atrial 
fibrillation), and 12p13 (NINJ2 gene, encoding a protein that is upregulated by 
nerve injury) could be added to the list of stroke-associated loci identified from 
earlier studies. The mechanistic basis for the associations with genetic markers 
across the spectrum of stroke-associated loci can now be explored and the 
genetic architecture of stroke.  
Factors predicting poor outcome (24) 
1. Age : more than 75 years 
2. Males : due to lack estrogen protective effect 
3. Risk factors : atrial fibrillation , DM , previous stroke 
4. Clinical findings 
• decreased consciousness at the onset 
• Presence of gaze deviation 
• Headache , nausea ,vomiting in first 24 hours 
• Elevated systolic BP >180 mm Hg on first day 
• Hyperthermia on admission 
• NIHSS score of 16 or more 
• Large vessel disease 
5. Laboratory findings 
• High glutamine in plasma > 200 micromol / L 
• CRP concentration > 10.2 mg / l within 72 hours 
• Hyperglycemia > 7mmol / l on admission. 
• Platelet count < 150000 due to increased bleeding 
6. Neuro imaging studies 
• Hyper density in a major intra cranial artery 
• Early CT changes within 6 hours of onset 
• >33 % of MCA territory involvement / multiple territory involvement 
with mass effect 
• Hemorrhagic transformation on follow up CT / on intra cranial 
  Doppler persisting MCA occlusion for hours 
• No flow on SPECT perfusion patterns 
• Carotid artery occlusion on conventional angiogram 
• MCA , basilar artery occlusion on angiogram 
• MRI – abnormal PWI in diffusion and perfusion weighted imaging 
• MRA – absence of MCA is associated with poor prognosis 
PROGNOSIS AND HYPERGLYCEMIA 
Already ample literature has demonstrated that hyperglycemia on 
admission is associated with worsened clinical outcome as reviewed in a 
systemic overview of thirty three studies(25). Glycemic control may be 
indicated also in non diabetic patients, in which stress hyperglycemia was 
associated with a three fold risk of fatal thirty day outcome and 1.4 fold risk in 
of poor functional outcome. 
Good glycemic control seems warranted also in hemorrhagic stroke, 
although more clinical information is needed in this area. At least two clinical 
trials have recently been initiated to examine the efficacy of early insulin 
therapy in acute stroke (26). Still there is no evidence to prove that the reversal 
of hyperglycemia improves the prognosis, as it has been demonstrated to do in 
acute myocardial infarction and in critically ill post surgical patients(27). 
Hyperglycemia and Thrombolytic Therapy of Acute Ischemic Stroke 
In several thrombolysis trials, hyperglycemia has been found to be 
associated with hemorrhagic events and was reconfirmed recently  as well as in 
a re-analysis of the NINDS rt-PA trial. (28,29,30).  In the latter study, an 
increase of admission glucose level was independently associated with 
decreased odds for neurologic improvement (odds ratio [OR]=0.76 per 100-
mg/dL increase in admission glucose) and the OR for symptomatic ICH   was 
1.75 per 100-mg/dL increase in admission glucose (95% CI 1.11 to 2.78, 
P=0.02)(31). The relationship was weaker after excluding patients with ICH, 
suggesting that admission hyperglycemia may exert its hazards in part through 
hemorrhagic events. However, another recent study by Alvarez-Sabin et al 
found admission glucose >140 mg/dL (OR 8.4, CI 1.8 to 40.0) to be the sole 
independent predictor of poor functional outcome at 3 months in patients with 
recanalization within 6 hours, even after excluding the patients with 
symptomatic ICH. (31). The same was not true for the patients who did not 
recanalize, which leads to speculation that hyperglycemia might partially 
preclude the beneficial effect of rtPA and early reperfusion.  
DIAGNOSTIC EVALUATION OF ISCHAEMIC STROKE(32) 
The diagnostic evaluation should include parallel assessment of the 
following. 
1. Imaging of the infarct 
2. Vascular studies 
3. Cardiac evaluation 
4. Hematological and other blood testing 
Imaging 
CT scan brain is done to differentiate hemorrhage from infarction. 
CT versus MRI 
1.  Only a minority infarction demonstrated within 24 hours on CT. MRI 
documents infarct as early 6 hours 
2.  Anatomic extent and vascular distribution are better delineated in 
MRI. Small infarctions are easily seen and white matter better 
visualized. 
3.  Posterior fossa infarctions are better visualized in MRI. 
TREATMENT 
The first goal is to prevent or reverse brain injury The second goal is to 
obtain an accurate understanding of the stroke mechanism so one can halt 
progression of brain injury or begin to prevent a second stroke. 
Treatments designed to reverse or lessen the amount of tissue infarction 
fall  within five categories: 
(1) Medical support 
(2) Thrombolysis 
(3) Anticoagulation 
(4) Antiplatelet agents 
(5) Neuroprotection 
(1)Medical Support 
 When cerebral infarction occurs, the immediate goal is to optimize 
cerebral perfusion in the surrounding ischemic area.  Preventing the common 
complications of bedridden patients like infections (pneumonia, urinary tract, 
and skin), deep venous thrombosis with pulmonary embolism.  Elevated BP 
should not be lowered unless there is malignant Hypertension or concomitant 
myocardial ischemia. If the blood pressure is low, raising it is advisable, using 
intravenous fluids or vasopressor drugs to enhance perfusion within the 
ischemic penumbra.  Treatment of cerebral edema if necessary 
(2)Thrombolysis 
The use of thrombolytic agents in acute cerebral infarction has been 
studied extensively. Angiography performed within a few hours of infarction 
frequently demonstrates arterial occlusions corresponding to patients 
presenting signs and symptoms. It is this association of arterial occlusion with 
acute neurological symptoms that prompted the study of thrombolytic agents 
in stroke patients. Agent used for this purpose is intravenous recombinant 
tissue plasminogen activator (rtPA) 
Indication  (33) 
• Clinical diagnosis of ischemic stroke with clear symptom 
• onset within 3 hours 
• CT scan showing no hemorrhage or significant edema 
• Age more than 18 years, Consent by patient or surrogate 
Contraindication 
Sustained BP > 185/110 
Platelets < 100,000; HCT< 25%; glucose < 50 or > 400 mg% 
Use of heparin within 48 hrs  and prolonged PTT, or elevated INR 
Rapidly improving symptoms 
Prior stroke or head injury within 3 months; prior intracranial hemorrhage 
Major surgery in preceding 14 days 
Minor stroke symptoms 
Gastrointestinal bleeding in preceding 21 days 
Recent myocardial infarction, Coma or stupor 
 
 
 
Administration of rtPA  
Intravenous access with two peripheral IV lines (avoid arterial or central 
placement) Review eligibility for rtPA (34). Administer 0.9 mg/kg 
intravenously (maximum 90 mg) IV as 10% of total dose by bolus, followed 
by remainder of total dose over 1 h. Continuous blood pressure monitoring. No 
other antithrombotic treatment for 24 h. For decline in neurological status or 
uncontrolled blood pressure, stop infusion, give cryoprecipitate, and re image 
brain immediately. Avoid urethral catheterization for > 2 h. 
(3)Anticoagulation 
The role of anticoagulation in atherothrombotic cerebral ischemia is 
uncertain. Heparinization is generally accomplished by beginning an infusion 
without bolus and is monitored to maintain the activated PTT at approximately 
twice normal. 
This regimen is maintained for 2 to 5 days. During this time the patient 
is monitored for hemorrhagic complications, the evaluation is completed 
decision is made regarding the need for carotid endarterectomy, long-term 
anticoagulation, or an antiplatelet therapy. If long-term anticoagulation is 
chosen, warfarin is administered and heparin discontinued when the 
international normalized ratio (INR) is in the range of 2 to 3. 
 
 
(4)Antiplatelet Agents 
Aspirin is the only antiplatelet agent that has been prospectively studied 
for the treatment of acute ischemic stroke. The use of aspirin within 48 hrs of 
stroke onset reduced both stroke recurrence risk and mortality minimally 
(5)Neuroprotection 
Neuroprotection is the concept of providing a treatment that prolongs 
the brain's tolerance to ischemia long enough to allow other measures to be 
employed to mitigate ischemia. Hyperthermia, hyperglycemia are the agents 
which increases the size of the infarct, hence hypothermia and normalizing 
blood sugar are powerful neuroprotective agents. 
Primary prevention 
1.Hypertension 
Antihypertensive treatment is recommended for both prevention of 
recurrent stroke and prevention of other vascular events in persons who have 
had an ischemic stroke or TIA and are beyond the hyperacute period. Because 
this benefit extends to persons with and without a history of hypertension, this 
recommendation should be considered for all ischemic stroke and TIA 
patients. An absolute target BP level and reduction are uncertain and should be 
individualized, but benefit has been associated with an average reduction of 
≈10/5 mm Hg, and normal BP levels have been defined as <120/80 mm Hg by 
JNC-7.  
Several lifestyle modifications have been associated with blood pressure 
reductions and should be included as part of a comprehensive antihypertensive 
therapy. The optimal drug regimen remains uncertain; however, the available 
data support the use of diuretics and the combination of diuretics and an ACE. 
The choice of specific drugs and targets should be individualized on the basis 
of reviewed data and consideration of specific patient characteristics (eg, 
extracranial cerebrovascular occlusive disease, renal impairment, cardiac 
disease, and diabetes).  
2.  Glycemic control 
More rigorous control of blood pressure and lipids should be considered 
in patients with diabetes. ACEIs and ARBs are more effective in reducing the 
progression of renal disease and are recommended as first-choice medications 
for patients with DM  Glucose control is recommended to near-normoglycemic 
levels among diabetics with ischemic stroke or TIA to reduce microvascular 
complications  and possibly macrovascular complications. The goal for 
hemoglobin A1c should be ≤7% .  
3. Cessation of smoking 
All healthcare providers should strongly advise every patient with stroke or 
TIA who has smoked in the last year to quit. Avoidance of environmental 
tobacco smoke is recommended. Counselling, nicotine products, and oral 
smoking cessation medications have been found to be effective in helping 
smokers to quit 
4.Treatment of dyslipidemia 
Hypertension is the most significant of the risk factors; in general, all 
hypertensives should be treated. Coronary artery disease is the most common 
cause of death in patients with cerebrovascular disease, treatment of 
hypercholesterolemia seems prudent for both the heart and brain. Tobacco 
smoking should be discouraged in all patients 
5.Antiplatelet Agents 
Platelet antiaggregation agents can prevent atherothrombotic events, 
including TIA and stroke, by inhibiting the formation of intra-arterial platelet 
aggregates. These can form on diseased arteries, induce thrombus formation, 
and occlude the artery or embolize into the distal circulation. The antiplatelet 
agents used for this purpose are Aspirin and Clopidogrel. 
6.Alcohol 
Patients with ischemic stroke or TIA who are heavy drinkers should 
eliminate or reduce their consumption of alcohol. Light to moderate levels of 
no more than 2 drinks per day for men and 1 drink per day for nonpregnant 
women may be considered. 
7. Obesity :  Weight reduction may be considered for all overweight ischemic 
stroke and TIA patients to maintain the goal of a BMI of between 18.5 and 
24.9 kg/m2 and a waist circumference of <35 in for women and <40 in for 
men. Clinicians should encourage weight management through an appropriate 
balance of calorie intake, physical activity, and behavioral counselling 
8.  Exercise 
For patients with ischemic stroke or TIA who are capable of engaging in 
physical activity, at least 30 minutes of moderate-intensity physical exercise 
most days may be considered to reduce the risk factors and comorbid 
conditions that increase the likelihood of recurrence of stroke. For those 
individuals with disability after ischemic stroke, a supervised therapeutic 
exercise regimen is recommended 
SURGICAL THERAPY 
Surgery for atherosclerotic occlusive disease is largely limited to carotid 
endarterectomy for plaques located at the origin of the internal carotid artery in 
the neck. Carotid endarterectomy is a proven effective prophylaxis against 
stroke and TIA. 
Stroke Centers and Rehabilitation 
Comprehensive stroke units that care for the acute patient followed by 
rehabilitation services have been shown to improve neurological outcomes and 
reduce mortality. Proper rehabilitation of the stroke patient includes early 
physical, occupational, and speech therapy. It is directed toward educating the 
patient and family about the patient's neurological deficit, preventing the 
complications of immobility (e.g., pneumonia, deep vein thrombosis and 
pulmonary embolism, pressure sores of the skin, muscle contractures), and 
providing encouragement and instruction in overcoming the deficit. The goal 
of rehabilitation is to return the patient to home and to maximize recovery by 
providing a safe, progressive regimen suited to the individual patient. 
INTRA CEREBRAL HEMORRHAGE 
Intra cerebral hemorrhage accounts for approximately 15%-25% of the 
strokes. The overall mortality for this type subtype of stroke is from 25 % to 
60% In nearly 70% of patients Hypertension is the commonest cause of bleed. 
The lipohyalinosis of the small intraparenchymal arteries is the leading 
cause of hemorrhage. The micro aneurysms of Charcot and Bouchard is 
uncertain, but they are found at anatomical sites preferentially affected by 
ICH. 
Hyperglycemia and hemorrhagic stroke : 
Incidence of hemorrhagic stroke is higher in diabetes either known 
diabetes or newly detected diabetes. This is due to the fact that blood brain 
barrier is disrupted by chronically elevated hyperglycemia which is dealt 
earlier in the topic ‘thrombolysis of ischemic patients with hyperglycemia’ 
The non hypertensive causes include following : 
1. bleeding disorders, anticoagulant and fibrinolytic treatment 
2. cerebral amyloid angiopathy 
3. granulomatous angitis of the CNS 
4. sympathomimetic agents 
5. trauma 
6. hemorrhagic infarction 
7. vascular malformations 
8. Intracranial tumors 
Clinical features: 
symptoms of increased ICT 
symptoms that are specific for the location of the hematoma 
focal neurological deficits 
Imaging 
The CT scan is sensitive to the high density fresh blood in the 
parenchyma while MRI can determine the time duration between the 
hemorrhage and the MRI examination common sites : 
1 . Putamen - 35 % 
2 . Lobar – 25 % 
3 . Thalamus – 10-15 % 
4 . Caudate nucleus – 5 % 
5 . Pons – 5 % 
6. Cerebellum – 5 – 10 % 
 
Treatment 
• Control of hypertension 
• Air way maintenance if the GCS is less than 8 
• Treatment of coagulation abnormalities 
• Protamine sulfate is used if the hemorrhage is due to heparin 
• Cryoprecipitate is used if the hemorrhage is due to heparin 
• Measures for the prevention of further elevation of ICP 
Routine anticonvulsants are not recommended in patients who do not 
have seizures at onset due to negligible risk of subsequent epilepsy in them. 
Patients with lobar hemorrhage and cerebellar hemorrhage can be managed 
surgically whereas the deep hemorrhages are managed medically. 
MORTALITY IN STROKE: 
Early mortality (first thirty days ) : 
Generally death occurs with in the first day and is secondary to large 
infarction leading to cerebral edema and raised Intra cranial tension. These 
patients can be clinically identified by 
1. Fall in level of consciousness. 
2. Gaze paresis. 
3. Hemianopia. 
4. Dilated pupil on the infracted side. 
5. Abnormal type of respiration. 
In such patients CT scan will reveal large hemispherical infarct with 
edema and midline shift and or brain stem infarct. 
Other causes after 10 days : 
1. Aspiration pneumonitis. 
2. Bed sores. 
3. Infections. 
4. Pulmonary embolism. 
Late mortality : 
Important causes are IHD and recurrent stroke. 
SUMMARY OF EVIDENCE SUPPORTING A DETRIMENTAL ROLE 
FOR ELEVATED GLUCOSE IN STROKE 
1.  Experimental ischemic damage is worsened by hyperglycemia 
2.  Experimental ischemic damage is reduced by glucose reduction 
3.  Early hyperglycemia is associated with clinical infarct progression 
in brain imaging 
4.  Early hyperglycemia is associated with hemorrhagic conversion in 
stroke 
5.  Early hyperglycemia is associated with poor clinical outcome 
6. Early hyperglycemia may reduce the benefits of recanalization 
7.  Immediate insulin therapy reported beneficial in acute myocardial 
infarction and surgical critical illness. 
  
 
 
 
 
3.  AIM AND OBJECTIVES 
 
To measure the blood glucose level within twenty four hours of the 
onset of stoke in both diabetics and in non diabetics and to evaluate the 
severity and prognosis in both diabetics and non diabetics in relation to 
hyperglycemia. 
 
 
 
 
 
                                   
 
 
 
4. MATERIALS AND METHODS 
A total of hundred and eleven patients of acute stroke admitted in the 
department of medicine Government Rajaji Hospital Madurai between April 
2011 and September 2011 were studied. The patients were selected on the 
following basis 
INCLUSION CRITERIA: 
1.  Patients above 40 years 
2.  Patients admitted within twenty four hours of onset of symptoms 
3.  Patients should not be a known case of cerebro vascular accident 
4.  Blood sugar recorded with in twenty four hours of the onset of stroke 
EXCLUSION CRITERIA: 
1.  Patients admitted after twenty four hours of stroke 
2.  Those patients who received intravenous glucose before or during study 
period 
3.  Patients for whom information about diabetes could not be obtained 
4.  Patients who died before it could be established whether or not they 
had diabetes 
5.  Illness presented with stroke like symptoms 
Out of the hundred and eleven patients, eleven were dropped as follow 
up could not be done. 
Complete history was taken, clinical examination was done and clinical 
diagnosis for each patient was arrived. 
Blood pressure measurement , blood sugar, urea, creatinine, electrolytes, 
hemoglobin, total count, differential count; urine sugar, albumin, deposits; 
electrocardiogram and chest X ray done for all patients The severity of stroke 
for each patient is calculated based on NIH stroke scale, which takes the 
following clinical findings in to account and each criteria awarded specific 
points(35). 
1a Level of conscious  1b LOC questions  
Alert  
Drowsy  
Stuporous  
Comatose  
0 
1 
2 
3 
Answers both correctly  
Answers one correctly  
Incorrect  
 
0 
1 
2 
 
1c LOC commands    
Obeys both correctly  
Obeys one correctly  
Incorrect  
0 
1 
2 
  
2.  Gaze palsy  3.  Visual  
Normal  
Partial gaze palsy  
Forced deviation  
0 
1 
2 
No visual loss  
Partial hemianopia  
Complete hemianopia  
Bilateral hemianopia  
0 
1 
2 
3 
4 Facial palsy  5 Best motor arm/ leg 
(right/left) 
 
Normal symmetric  
Minor paralysis  
Partial paralysis  
Complete paralysis  
0 
1 
2 
3 
No drift  
Drift  
Some antigravity effect  
No antigravity effect  
No movement  
0 
1 
2 
3 
4 
6 Limb ataxia  7 Sensory  
Absent  
Present in one limb  
Present in both limbs  
0 
1 
2 
No sensory loss  
Mild to moderate 
sensory loss  
Total sensory loss 
0 
1 
2 
8  Language  9 Dysarthria  
Normal, no aphasia  
Mild to moderate aphasia  
Severe aphasia  
Mute, global aphasia  
0 
1 
2 
3 
Normal  
Mild to moderate  
Severe  
0 
1 
2 
10 Extinction/ inattention    
No abnormality  
Visual/ tactile/ spatial/ 
personal inattention  
Profound hemi inattention  
0 
1 
 
2 
  
 
 
The points were added, with a maximum of thirty points. Once clinical 
diagnosis of acute stroke is made venous blood sample is taken, with in twenty 
four hours of onset of symptoms, and sent to laboratory for glucose estimation. 
In patients with blood sugar more than 6.1 mmol / l(110 mg/dl)  and 
with out a history of diabetes, Hemoglobin A 1c was performed.  Hence the 
patients can be classified into four groups (36). 
Blood sugar less than 6.1 mmol/l  : Non diabetic (euglycemic) 
History of diabetes    : Known diabetics 
Blood sugar more than 6.1mmol/l, no history of diabetes, and hemoglobin A1c 
more than 6.4%   : Newly detected diabetics 
Blood sugar more than 6.1 mmol/l, no history of diabetes, and hemoglobin 
A1c less than 6.4%    : Stress hyperglycemics 
 
Then computerized tomography, CT, of the brain was performed in all 
patients to : Confirm the diagnosis 
Detect the type of stroke 
Detect the size of lesion (small < 5mm; Medium 5 – 10 mm; 
Large > 10 mm or involving more than one vascular territory) 
Locate the site of lesion 
Identify the presence of cerebral edema or midline shift 
The patients were followed up for thirty days and outcome in the form 
of death ; poor, moderate and good improvement were recorded. Patients who 
were  
unable to return to any form of work( (37),  
persistent Disability need for residential placement(38),  
dependent in activities of daily  
living and stable deficit with no recovery(39)  
were classified as those with poor outcome. Patient whose  
symptoms improved,  
who were independent in attending day to day activities, 
improvement in motor function and aphasia and  
no persistent disability  
were grouped as patients with good outcome. Patients who fared in between 
these two groups were grouped as those with moderate outcome. 
 
 
Statistical Tools  
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and 'p' values were calculated. Kruskul Wallis chi-square  
test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
 
 
 
 
 
 
 
 
 
 
 
  
5. RESULTS AND OBSERVATION 
Table - 1 
Age distribution 
Age group Cases 
No % 
40 - 49 years 12 12 
50-59 years 34 34 
60-69 years 36 36 
70 years & above  18 18 
Total 100 100 
Range 40 – 80 years 
Mean 59.4 years 
SD 8.7 years 
 
 Age group of patients included in the study ranged from 40 years to 80 
years with a mean of 59.4 years. 
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Table - 2 
Sex distribution 
Sex Cases 
No % 
Male 68 68 
Female 32 32 
Total 100 100 
 
 68% of cases included in the study were males and 32% were females.             
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Table - 3 
Type of diabetes 
 
Type of diabetes Cases 
No % 
Euglycemia 47 47 
Stress hyperglycemia 12 12 
Known DM 22 22 
Newly diagnosed DM 19 19 
Total 100 100 
 
 Among the four types of diabetes cases in the study group, euglycemia 
was the most common type (47%). 
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Table - 4 
Prognosis 
 
 
Prognosis 
Cases 
No % 
Good 34 34 
Moderate 26 26 
Poor 16 16 
Death 24 24 
Total 100 100 
 
   40% of the study cases had bad prognosis. 
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Table - 5 
Type of stroke 
 
Type of stroke Cases 
No % 
Infarction 70 70 
Hemorrhage 30 30 
Total 100 100 
 
  70% of cases had infarction and 30% had hemorrhage. 
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RELATIONSHIP BETWEEN PROGNOSIS AND OTHER 
PARAMETERS 
 
Table - 6 
Age and prognosis 
Prognosis Age in years 
Mean SD 
Good 58.2 7.9 
Moderate 61.1 10.6 
Poor 60.3 9.7 
Death 58.5 7.6 
‘p’ 0.7439 
Not significant 
 
 
 
 
 
 
 
  
 
 
Table - 7 
Sex and prognosis 
 
Prognosis Sex 
Males ( 68) Females ( 32) 
No % No % 
Good 23 33.8 11 34.4 
Moderate 20 29.4 6 18.7 
Poor 9 13.2 7 21.9 
Death 16 23.5 8 25.0 
 
 Nearly 63% of the males and 53% of the females had favourable 
prognosis. 
 
 
 
 
 
 
  
 
Table - 8 
Prognosis and other quantitative variables 
 
Prognosis  Mean +SD 
SBP DBP Blood sugar HbA1C NIHSS 
Good 144.4 +25.8 85.5 +10 95.4 +10 6.07 +0.08 7.88 +3.83 
Moderate 154.5 +24.8 88 +11.9 140.9 +49.7 6.95 +1.5 10.73 +4.34 
Poor  154.4 +25 90 +12.6 183.1 +46.4 8.06 +1.58 14.56 +4.27 
Death 174.7 +32.4 95.8 +14.4 235.3 +56.3 8.53 +1.62 21.83 +4.47 
‘p’ 0.0014 
Significant 
0.0436 
Significant 
0.0001 
Significant 
0.0001 
Significant 
0.0001 
Significant 
 
 Patients with adverse prognosis had higher B.P., blood sugar, HbA1C 
and NIHSS values than persons with better prognosis. This relationship was 
statistically significant ( p > 0.05). 
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Table - 9 
Prognosis and type of diabetes 
 
 
Type of diabetes 
Prognosis 
Good Moderate Poor Death 
No % No % No % No % 
Euglycemia ( 47) 32 68.1 10 21.3 2 4.3 3 6.4 
Stress hyperglycemia (12) 2 16.7 7 58.3 3 25 - - 
Known DM ( 22) - - 5 22.7 7 31.8 10 45.5 
Recently diag. DM (19) - - 4 21.1 4 21.1 11 57.9 
 
 Percentage of death and poor prognosis were more in recently diagnosed 
and known DM cases than in the other two types of diabetes. 
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Table - 10 
Prognosis and type of stroke 
 
 
Type of stroke 
Prognosis 
Good Moderate Poor Death 
No % No % No % No % 
Infarction (70) 33 47.1 17 24.3 6 8.6 14 20 
Hemorrhage ( 30) 1 3.3 9 30 10 33.3 10 33.3 
‘p’ 0.0008 
Significant 
 
 More than 70% of infarction cases had favorable prognosis whereas this 
percentage was less than 35% in hemorrhage cases. This difference was 
statistically significant ( p = 0.0008). 
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Table - 11 
Type of diabetes and presence of risk factors 
 
Type of diabetes  Risk factor 
Present ( 83) Absent ( 17) 
No % No % 
Euglycemia 37 44.6 10 58.8 
Stress hyperglycemia 22 26.5 - - 
Known DM 13 15.7 6 35.3 
Recently diagnosed DM 11 13.3 1 5.9 
 
 
 
 
  
 
 
 
Table - 12 
Type of diabetes and other quantitative parameters 
 
Type of diabetes Mean +SD 
Blood sugar HbA1C NIHSS 
Euglycemia 97.5 +11.9 6.1 +0.19 9.11 +5.16 
Stress Hyperglycemia 120.6 +2.8 6.09 +0.07 12.42 +3.94 
Known Diabetes mellitus 230.3 +39.8 8.77 +1.29 15.73 +6.75 
Recently diagnosed  DM 231 +32.9 8.93 +1.41 20.05 +5.04 
P 0.0001 
Significant 
0.0001 
Significant 
0.0001 
Significant 
 
 Mean B.P, blood sugar, HbA1C and NIHSS values were maximum in 
recently diagnosed DM cells followed by known DM cases. The values were 
lower in the other two types. The differences were statistically significant ( p < 
0.05). 
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 Table - 13 
Type of diabetes and type of stroke 
 
 
Type of diabetes  
Type of stroke 
Infarction Hemorrhage 
No % No % 
Euglycemia (47) 41 87.2 6 12.8 
Stress hyperglycemia (12) 11 91.7 1 8.3 
Known DM (22) 10 45.5 12 54.5 
Recently diag.  DM(19) 8 42.1 11 57.9 
 
 Nearly 90% of euglycemia and stress hyperglycemic cases had 
infarction whereas less than 50% of known and recently diagnosed DM cases 
had hemorrhage. 
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Table - 14 
Type of stroke and other quantitative variables 
 
Variable  Mean + SD for  ‘p' 
Infarction Hemorrhage 
Blood sugar 135.3 +61.8 200.6 +61.7 0.0001 
Significant 
HbA1C 6.78 +1.39 8.24 +1.62 0.0001 
Significant 
NIHSS 11.7 +6.4 16.2 +6.8 0.0008 
Significant 
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6. DISCUSSION 
Age sex and risk factors 
Our study of hundred patient showed a male preponderance which is 
commonly seen with most other studies. Majority of patients, (36%) were 
between 60-69 years. Among our study group 63% of males and 53% of the 
females had a favourable prognosis. More than half of the patients were 
smokers and one third had history of alcohol intake. 
Glycemic status 
In our study group, 53 patients had elevated admission day blood sugar 
level out of which 19% were newly diagnosed diabetics, 12% were stress 
hyperglycemics, 47% were euglycemics, 22% were known diabetics.  Nearly 
90% of the euglycemic  and stress hyperglycaemic patients had infarction 
where as less than 50% of known diabetics and newly diagnosed patients had 
infarction. 
Severity of stroke 
Severity of stroke was assessed with NIH Stroke scaling system. 
Admission day hyperglycaemic patients had a higher score when compared to 
Euglycemic patients (17.89 vs. 9.11 respectively), which was statistically 
significant ( p = 0.0001). Among the admission day hyperglycaemic patients 
newly detected diabetes had the higher  mean NIHSS values than euglycemic 
patients. Hence elevated blood sugar level at the time of admission was found 
to correlate with increasing severity of stroke. 
SIZE OF LESION 
The size of the lesion was analyzed with the help of CT brain. Most of 
the euglycemic patients had small sized infarcts and hemorrhage whereas 
majority of the admission day hyperglycemic patients had a larger sized lesion 
with edema and midline shift which was found to be statistically significant    
(p = 0.0001). Hyperglycemia by virtue of increased anaerobic metabolism, 
increased brain lactate, impaired mitochondrial function, vascular disease, 
increased free radical production, increased expression of c-fos and cox-2 
causes severe brain injury and large sized infarcts. Hyperglycemia can disrupt 
the blood brain barrier resulting in increased changes for hemorrhage and 
hemorrhagic transformation of infarcts 
TYPE OF STROKE: 
Among the euglycemic group eighty seven percent of the patients had 
Ischemic stroke and thirteen percent had hemorrhagic stroke. Among patients 
with admission day hyperglycemia, in the newly detected patients 57.9% had 
hemorrhagic stroke followed by 54.5% in known diabetes patients and 8.3% in 
stress hyperglycemics and half of them had hemorrhagic stroke. Our study 
shows an increasing incidence of hemorrhagic stroke among diabetic patients.  
OUTCOME OF STROKE: 
         In this study euglycemic patients had a better outcome when compared to 
admission day hyperglycemic patients. Sixty eight percent of euglycemic 
patients had a good functional recovery. On the contrary only 16.7% of 
admission day stress hyperglycemic patients had good functional recovery at 
the end of thirty day follow up.  
        The mortality rate was 6% among euglycemic patients which was much 
less when compared to those of hyperglycemic patients (>50%). Among 
euglycemic patients 21.3% had moderate prognosis and which was 58.3% of 
stress hyperglycemic patients. Poor outcome was noticed in 4% of euglycemic 
patients where as 26% of hyperglycemic patients had poor prognosis. Hence 
there was an increased risk of early mortality in admission day hyperglycemic 
patients when compared to euglycemics.  
         In the ischemic stroke group early mortality was noticed in 11.5% of 
euglycemic patients and 78% of hyperglycaemic patients.  88% of euglycemic 
patients and 22% of hyperglycaemic patients had good prognosis. Hence 
hyperglycemia was associated with an increased early mortality rate and poor 
functional outcome in ischemic stroke group which was also statistically 
significant ( P : 0.0001). 
       In hemorrhagic stroke group early mortality was noticed in 28% of 
euglycemic patients and 78% of hyperglycaemic patients which is statistically 
significant ( P  0.0256). 
     In nondiabetic ischemic group stress hyperglycemia had poor outcome 
when compared with euglycemic group. Poor outcome was 23% in stress 
hyperglycemic group where as 4.3% in euglycemic group. 
     HbA1C was found to be low in euglycemic group and elevated in 
hyperglycemic group which is also statistically significant (P.0001). 
         Patients with associated with additional risk factors like hypertension 
coronary artery disease had high mortality rate than normal patients which was 
also statistically significant. (P < 0.05) 
In our study the HbA1C was 6.78 among ischemic stroke patients where 
as 8.24% among hemorrhagic stroke patients. Our study clearly shows a 
positive correlation   between admission day sugar value and the outcome of 
stroke. Higher admission day elevated blood glucose level has increased 
mortality and high risk of poor functional recovery. 
COMPARISION WITH OTHER STUDIES : 
                 According to Perttu J. Lindsberg and Risto o Roine hyperglycemia 
was noted in two third ( 66% ) of all ischemic stroke patients(40). 
In our study hyperglycemia was noticed in 53% of patients. In their study 
known diabetes and newly diagnosed diabetes contributed one third of cases    
( 33% ). In our study the same group contributed to 41%. 
                A study published in European Journal of Neurology 2002, 
concluded that elevated glucose level after acute stroke is associated with 
higher stroke severity than those with normal level(41). The mean NIHSS was 
9.11 in euglycemics and 17.89 in hyperglycemic patients in our study. 
            In the journal of clinical endocrinology and metabolism 2002, a study 
confirmed that patients with newly detected hyperglycemia had a significant 
higher early mortality and a lower functional outcome than patients with a 
history of diabetes or normoglycemia (42). Our study in hundred acute stroke 
patients had similar results. 
        In hemorrhagic stroke patients, admission hyperglycemia was associated 
with higher mortality in both diabetic and non diabetics patients. In our study, 
in ischemic patients, who had elevated admission day glucose level 
experienced a six and half fold increased early mortality than euglycemics(43). 
In hemorrhagic stroke group there was a two and half risk of increased 
mortality in hyperglycemics when compared with euglycemics. Non diabetic 
stress hyperglycemic patients with ischemic stroke had five fold increased 
early mortality when compared to euglycemics. In the diabetic group since the 
sugar value before the onset of stroke was not known, the effect of stress in 
diabetic group could not be studied. 
           The study clearly shows an increased early mortality rate and poor 
functional recovery in patients with diabetes and stress hyperglycemia when 
compared to euglycemics. Hence there is an urgent need to confirm the 
improvement in these patients by normalizing blood sugar. Several trials are 
now under way to improve the outcome of stroke by normalizing the blood 
glucose with human recombinant insulin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
7. CONCLUSION 
 
There is a linear correlation between admission day hyperglycemia and 
stroke in its severity, size and outcome. The combined diabetes and stress 
hyperglycemics are found to have larger sized severe stroke and poor 
functional outcome in the form of increased mortality. There is a good 
correlation between admission day glucose level and the outcome in ischemic 
stroke. Admission day elevated glucose level was a significant predictor of 
mortality and poor functional outcome after acute stroke. Hence, restoration of 
normoglycemia as soon as possible should be encouraged though conclusive 
evidences are lacking. In the interim, we should fare well with adhering to 
good general stroke management, normalization of body temperature, fluid 
balance and hemodynamics or we may otherwise risk the favorable outcome 
even in the patients with normoglycemia. 
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9. PROFORMA 
 
NAME OF THE PATIENT :     IP NO : 
AGE :         SEX :  
ADDRESS :        OCCUPATION : 
CHIEF COMPLAINTS : 
HISTORY OF PRESENTING COMPLAINTS : 
PAST HISTORY : 
HT / DM / TIA / PT / BA / COPD / CRF / CAHD / DCMP / RHD / AS / 
MVP/ HEPATIC DISEASE / SEIZURES / PSYCHIATRIC DISORDERS 
PERSONAL HISTORY :  
SMOKING, ALCOHOLISM, DIET 
GENERAL EXAMINATION : 
VITALS :  
BP, PULSE RATE, RESPIRATORY RATE AND PATTERN 
CLINICAL EXAMINATION : 
CENTRAL NERVOUS SYSTEM : 
CARDIOVASCULAR SYSTEM : 
RESPIRATORY SYSTEM : 
ABDOMEN EXAMINATION : 
SPINE AND CRANIUM : 
CLINICAL DIAGNOSIS : 
 
INVESTIGATIONS : 
Blood sugar , urea , Serum creatinine 
Serum electrolytes : sodium, Potassium 
Blood hemoglobin , TC , DC, ESR 
Urine albumin , sugar , deposits 
Total cholesterol 
Electrocardiogram 
Chest X ray 
CT scan brain 
Glycosylated Hemoglobin when required 
FINAL DIAGNOSIS 
PROGNOSIS (30 DAY FOLLOW UP) : 
 Good / Moderate / Poor / Death 
 
 
 
 
 
 
 
 
 
      
MASTER CHART 
   
S.No. Name Age Sex 
Past 
History BP NIHss Sugar HBA1c CT Brain Prognosis 
1 Chandran 80 M HT/DM 170/100 15 180 8 LFP Moderate 
2 Rajan 65 M HT 170/90 7 112 6.1 LF/VS Good 
3 Padma 54 F DM 130/80 8 220 9.4 LPH Poor 
4 Ranjanbeevi 60 F HT/DM 150/100 16 300 10.2 RCH Death 
5 Muniammal 60 F DM/HT 120/80 20 270 9 RFP/MLS Death 
6 Raman 80 M HT 170/100 9 113 6 LPT/VS Moderate 
7 Antony 50 M - 130/80 20 284 11 LPT Moderate 
8 Arokyam 65 M S/A/HCH 130/80 7 96 6.1 RF Good 
9 Sakthi 68 F HT 170/86 23 101 6 LCG Good 
10 Paramasivam 52 M DM/S 130/80 23 270 10.2 LFP Death 
11 Mohamed 70 M HT 160/90 4 90 6.1 LF Good 
12 Santhiya 70 F - 130/80 10 116 6.1 LCG Good 
13 Kanthan 50 M - 130/80 15 215 10 LPH Poor 
14 Chitra 60 F HCH 140/80 8 88 6 RF Good 
15 Papathi 75 F - 130/80 10 116 6.1 RPT Moderate 
16 Saleema 75 F HT 200/110 12 198 7 LFP/MLS Death 
17 Ravi 55 M HT/S/A 170/100 8 92 7.1 RCH Moderate 
18 Narayanan 80 M HT 180/110 12 98 6.5 LF Poor 
19 Narasimman 60 M DM/S 130/80 8 260 9 LFP Death 
20 Arunachalam 60 M HT/CAD 160/90 8 90 6.1 RCH Moderate 
21 Manohar 48 M S/A 120/84 7 98 6 LCG Good 
22 Arumugam 70 M HT 170/100 10 118 6.1 LPT Moderate 
23 Murthy 58 M HT/DM 180/90 23 280 10.6 PRT Death 
24 Leelavathy 55 F - 200/110 25 236 8 LFPH Death 
25 Vadiyu 70 F HT 170/110 16 210 9.6 LFPH Poor 
26 Muniyandi 75 M - 120/80 7 90 6 LLCG Good 
27 Prema 48 F HCH 130/80 7 88 6 LF Good 
28 Palani 47 M DM/CAD 140/80 16 200 8 LTH Poor 
29 Arumugan 70 M HT 170/104 12 118 6.1 LPT Moderate 
30 Kanaga 70 F HT 200/110 25 212 8 RFP/MLS Death 
31 Ramalingam 55 M S/A/HCH 120/80 9 120 6.2 RFT Moderate 
32 Ponniammal 70 F HT/HCH 170/110 16 124 6 LFP/MLS Poor 
33 Abdul Kadhar 50 M HT/DM/S 200/110 24 220 6.9 LFP/MLS Death 
34 Murugan 47 M DM/CAD 130/80 16 230 8 LFH Poor 
35 Manohar 48 M S/A 130/70 7 98 6 LCG Good 
36 Munusamy 60 M - 130/80 4 88 6.1 LF Good 
37 Sonali 75 F HT 200/100 23 140 6.4 LPH/MLS Death 
38 Manikandan 63 M DM 140/70 7 170 7.4 RCG Moderate 
39 Narayanan 60 M DM/OCM 120/80 10 220 8.4 LPH Poor 
40 Mani 55 M DM/S 130/70 24 276 9.8 RFP/MLS Death 
41 Boopalan 48 M S/A/HCH 130/84 5 90 6.1 LCG Moderate 
42 Annammal 74 F HT 140/90 7 80 6 RCG Good 
43 Indirani 60 F DM/HCH 130/80 7 120 6.2 LCG Good 
44 Panchacharam 53 M HT/S/A 200/110 23 188 6.8 RFP/MLS Death 
45 Parvathy 55 F - 130/80 10 108 6 RCG Moderate 
46 Rajendran 49 M HIS 180/100 10 194 10 LPH Moderate 
47 Munusamy 60 M - 130/80 4 88 6.2 LF Good 
48 Dasanathan 80 M - 120/80 8 115 6.1 LPT Moderate 
49 Santhanam 55 M S/A 130/80 5 90 6 LCG Good 
50 Gajendran 55 M - 140/80 20 232 8 LFP/MLS Death 
51 Ranganayagi 64 F HT 200/110 25 246 7.8 RPH/MLS Death 
52 Cinnathai 68 F DM 140/70 15 121 6.1 LPT Moderate 
53 Amir 60 M CAD/DM 140/88 8 198 7.4 RCH Poor 
54 Krishnan 55 M HT/S/A 176/96 5 84 6 LCH Good 
55 Ramu 50 M HCH/DM 170/100 16 216 8 RFP/MLS Death 
56 Akthar 50 M HT 170/90 10 121 6.1 RFP Moderate 
57 Andal 60 M RHD/AF 104/80 7 86 6 LF Good 
58 Raja 65 M HT/CAD 176/100 14 198 10.4 RPH Moderate 
59 Pitchai 65 M S/A 130/82 14 120 6.1 LPT/MLS Poor 
60 Ramayee 52 F HT 170/90 17 124 6 LPT Poor 
61 Muthu 60 M HT 130/100 7 89 6.2 LCG Good 
62 Narayanan 50 M HT/S/HCH 172/100 25 284 10.4 RFP/MLS Death 
63 Raghu 54 M HT/DM 180/90 7 90 6 LPT Good 
64 Balan 60 M HT/S/A 200/11 10 100 6 LCH Moderate 
65 Doss 70 M HT 200/110 25 101 6 RPT/MLS Death 
66 Sethu 54 M S 120/70 10 110 6 LF Moderate 
67 Guru 65 M DM/S/HCH 130/70 25 204 8 LFPH Poor 
68 Santhy 60 F HT 190/110 7 100 6 RCG Good 
69 Naren 50 M HT/S/HCH 172/100 25 200 8 RPH Moderate 
70 Ramasamy 60 M HT/DM 190/90 10 188 - RPH Moderate 
71 Ismail 57 M - 120/80 7 90 6.2 RCG Good 
72 Fathima 60 F HT 170/90 17 120 6.1 RCG Good 
73 Sankar 48 M HT 180/90 7 96 6 LF Good 
74 Arul 50 M HT/DM 190/100 10 200 9 RPH Poor 
75 Solai 56 M HT 190/80 12 100 6.2 LCG Good 
76 Gowri 60 F HT 190/100 18 125 6.1 RPH/MLS Poor 
77 Narmatha 62 F - 120/80 16 104 6 LCG Good 
78 Lakshmi 70 F HT/CAD 170/90 16 220 10 RPT Poor 
79 Natraj 45 M S/A 130/70 10 121 6 PFP Moderate 
80 Balamurali 49 M HT/DM 190/90 24 280 11 LPH/MLS Death 
81 Chokki 50 F DM 170/80 5 206 8 LCG Moderate 
82 Kuppusamy 60 M HT/S/A 180/110 7 90 6.2 LTHA Good 
83 Sundar 60 M - 130/80 24 280 9 RPH/MLS Death 
84 Alagammal 65 F HT/DM 180/90 14 192 6.9 RPH Moderate 
85 Balu 50 M HT/DM 190/80 24 287 11 LPH/MLS Death 
86 Ramani 60 M DM 120/80 7 89 6 LF Good 
87 Nallan 58 M HT 210/120 23 240 7.2 LFPH/MLS Death 
88 Rahimbai 65 M S/A/HCH 120/80 7 80 6 LFP Moderate 
89 Malar 67 F HT 160/90 8 118 6 RFH Moderate 
90 Alagu 52 F - 130/80 7 100 6.2 RCG Good 
91 Raman 60 M S/HCH 120/80 7 97 6.1 LF Good 
92 Nelakandan 58 M HT/S 210/110 23 240 7.4 LFPH/MLS Death 
93 Raghu 54 M HT/S/A 180/90 7 89 6 LPT Good 
94 Anthony 60 M HT 210/90 25 101 6.4 RPT/MLS Death 
95 Laxmanan 52 M S/A 120/70 6 92 6 LCG Good 
96 Andal 47 M HT 180/110 6 89 6.1 LTHA Good 
97 Lashmi 65 F CAD/HT 180/90 16 222 10.4 LPT Poor 
98 Kuppam 56 M - 130/80 8 108 6 LCG Good 
99 Sundarambal 56 F - 130/80 24 290 10.6 RPH/MLS Death 
100 Mangalam 40 F RHD/MS 130/80 7 89 6.2 RF Good 
 
 
 
 
 
 
 
 
MASTER CHART ABBREVIATIONS 
 
 
HT   –  Hypertension  
DM   –  Diabetes  
 S   –  Smoker  
 A   –  Alcohol  
CAD   –  Coronary Artery Disease  
Hb A1c  –  Glycosylated haemoglobin  
 L   –  Left  
 R  –  Right  
 FI  –  Frontal infarct  
FPI  –  Fronto parietal infarct  
FH   –  Frontal Haemorrhage  
FPH   –  Fronto parietal haemorrhage   
PH   –  Parietal haemorrhage  
MLS   –  Midline shift 
PTH   –  Parito temporal haemorrhage  
CH  –  Capsulo ganglion haemorrhage  
CG   –  Capsule ganglion infarct  
PT   –  Parieto temporal infarct  
THA   –  Thalamic infarct 
AF   –  Atrial Fibrillation  
HCh   –  Hyper Cholesterolemia  
SUGAR  –  Admission day blood glucose level  
RHD   –  Rheumatic heart disease    
DCM  –  Dilated cardio myopathy  
